Viralgen Vector Core is a leading Contract Manufacturing Organisation (CMO) and Contract Development and Manufacturing Organisation (CDMO) specialising in the production of recombinant adeno-associated virus (rAAV) viral vectors. Established in 2017, the company has developed an advanced facility that optimises throughput and efficiency through its proprietary Pro10™ suspension manufacturing platform. This innovative technology supports industry-leading scalability, reproducibility, and speed to market, enabling the delivery of high-quality rAAV vectors for life-saving genetic medicines.

Services include:
- Cell and Gene Therapy
- Regulatory Services
- Injectables
- Clinical Dose
- Packaging

Viralgen Vector Core combines decades of experience in technology and drug development, offering best-in-class service to the gene therapy market. For more information, please visit viralgenvc.com.